Zenas BioPharma, Inc.

ZBIO · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
Operating Activities
Net Income-$156,988-$37,124-$119,282
Dep. & Amort.$137$113$78
Deferred Tax$0$0$0
Stock-Based Comp.$10,821$3,495$737
Change in WC$25,431-$8,039$7,967
Other Non-Cash$925$11,026$44,848
Operating Cash Flow-$119,674-$30,529-$65,652
Investing Activities
PP&E Inv.-$131-$17-$198
Net Acquisitions$0$0$0
Inv. Purchases-$36,421$0$0
Inv. Sales/Matur.$6,000$0$0
Other Inv. Act.$0$0-$2,000
Investing Cash Flow-$30,552-$17-$2,198
Financing Activities
Debt Repay.$0$20,000$0
Stock Issued$240,636$116$0
Stock Repurch.$0$0$0
Dividends Paid$0$0$0
Other Fin. Act.$172,322$0$59,391
Financing Cash Flow$412,958$20,116$59,391
Forex Effect$157$78-$41
Net Chg. in Cash$262,889-$10,352-$8,500
Supplemental Information
Beg. Cash$56,943$67,295$75,795
End Cash$319,832$56,943$67,295
Free Cash Flow-$119,805-$30,546-$67,850
Zenas BioPharma, Inc. (ZBIO) Financial Statements & Key Stats | AlphaPilot